标题：Research Grade Monalizumab 莫那利珠单抗,AntibodySystem Laboratories
链接：https://www.antibodysystem.com/product/266.html
名称：Research Grade Monalizumab莫那利珠单抗
别名：Monalizumab莫那利珠单抗，IPH-2201, NN-8765, NNC-0141-0000-0100, NNC-141-01000, monolizumab,anti-NKG2A, humZ270
CAS: 1228763-95-8
货号：DHD71901
适用物种：Human
寄主物种：Humanized
形式：Liquid
纯度：>95%
克隆性：Monoclonal
同种型：IgG4-kappa
应用：Research Grade Biosimilar
UniProt：P26715
靶点：KLRC1, NKG2-A/NKG2-B type II integral membrane protein, NKG2-A/B-activating NK receptor, CD159 antigen-like family member A, CD159a, NK cell receptor A, NKG2A
用途范围：仅用于科研
储存：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
免费热线：027-65279366 /18108604356
QQ：2663991332
咨询邮箱：products@biolabreagent.com
选购商城：https://www.antibodysystem.com
微信公众平台：佰乐博生物Biolab Reagents
参考文献：
Monalizumab: inhibiting the novel immune checkpoint NKG2A. PMID: 31623687
COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer. PMID: 35452273
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells. PMID: 30503213
Population Pharmacokinetics of Monalizumab in Patients With Advanced Solid Tumors. PMID: 36852723
Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors. PMID: 38309722
Unleashing NK- and CD8 T cells by combining monalizumab and trastuzumab for metastatic HER2-positive breast cancer: Results of the MIMOSA trial. PMID: 37393645
Monalizumab efficacy correlates with HLA-E surface expression and NK cell activity in head and neck squamous carcinoma cell lines. PMID: 36547689
Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial. PMID: 37707791
Immunotherapy in Head and Neck Cancer: Where Do We Stand? PMID: 37213060
Quantitative modeling predicts competitive advantages of a next generation anti-NKG2A monoclonal antibody over monalizumab for the treatment of cancer. PMID: 33501768
Intratumoral co-injection of NK cells and NKG2A-neutralizing monoclonal antibodies. PMID: 37782273
A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial. PMID: 34638090
NKG2A blocks the anti-metastatic functions of natural killer cells. PMID: 36787695
Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221. PMID: 31308062
[New frontiers in the fight against cancer]. PMID: 30973133
Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma. PMID: 35254876
NKG2A Immune Checkpoint in Vδ2 T Cells: Emerging Application in Cancer Immunotherapy. PMID: 36831606
Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using Monalizumab, Cholroquine, and antiviral agents. PMID: 32344314
NKG2A-checkpoint inhibition and its blockade critically depends on peptides presented by its ligand HLA-E. PMID: 35596615
The NKG2A-HLA-E Axis as a Novel Checkpoint in the Tumor Microenvironment. PMID: 32409305
Inhibitory NKG2A+ and absent activating NKG2C+ NK cell responses are associated with the development of EBV+ lymphomas. PMID: 37426645
Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia. PMID: 27853650
Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. PMID: 32967162
Killer to cure: Expression and production costs calculation of tobacco plant-made cancer-immune checkpoint inhibitors. PMID: 36811226
NK cell-based therapies for HIV infection: Investigating current advances and future possibilities. PMID: 34668588
Combined IL6 and CCR2 blockade potentiates antitumor activity of NK cells in HPV-negative head and neck cancer. PMID: 38468260
Targeting NKG2A to elucidate natural killer cell ontogenesis and to develop novel immune-therapeutic strategies in cancer therapy. PMID: 30645023
A novel Natural killer cell-related gene signature for improving the prediction of prognosis and immunotherapy response in bladder cancer. PMID: 37653625
Born to Kill: NK Cells Go to War against Cancer. PMID: 30898260
High-Density of FcγRIIIA+ (CD16+) Tumor-Associated Neutrophils in Metastases Improves the Therapeutic Response of Cetuximab in Metastatic Colorectal Cancer Patients, Independently of the HLA-E/CD94-NKG2A Axis. PMID: 34211852
